Skip to main content
. 2024 Aug 14;18(34):23757–23772. doi: 10.1021/acsnano.4c08811

Figure 2.

Figure 2

Antitumor effect and safety profiles of dextran conjugates. (A) Structure of DEX-0509A. (B–D) Antitumor effect of different sizes of dextran conjugates. EMT6-bearing mice (n = 5 per group) were intravenously injected once a week for 2 weeks with DSP-0509 (1 mpk) and different sizes of aminodextran-DSP0509 conjugates (0.2 mpk as the equivalent dose of DSP-0509). (B) Tumor sizes of each of the groups. Data are shown as mean ± SD. Statistical differences were evaluated by the parametric Dunnett test vs vehicle (PBS treatment) (*p < 0.01, **p < 0.001). (C) Weight changes of treated mice. (D) Individual tumor size in mice treated with vehicle, DSP-0509, 6 kDa aminodextran conjugates (6DEX-0509A), and 20 kDa aminodextran conjugates (20DEX-0509A). (E–G) Body temperature changes in tumor-bearing mice treated with 6DEX-0509A (E), 20DEX-0509A (F), and 20DEX-0509R (G). Mice were treated with each dextran (0.2 mpk as equivalent dose of DSP0509) at day 0 and day 7. Statistical differences were evaluated by the parametric Dunnett test. *p < 0.05 vs 0 min. (H, I) Comparison of the anti-EMT6 tumor effect of 6DEX-0509A and cytokine profiles in injected mice. EMT6-bearing mice (n = 6 per group) were intravenously injected once a week for 3 weeks with DSP-0509 (5 mpk) and 6DEX-0509A (0.2 mpk as equivalent dose of DSP-0509). (H) Tumor sizes of each of the groups. Data are shown as mean ± SD. Statistical differences were evaluated by the parametric Dunnett test vs vehicle (PBS treatment) (*p < 0.05). (I) Blood cytokine profiles. EMT6-bearing mice were intravenously injected once with DSP-0509 (5 mpk) and 6DEX-0509A (0.2 mpk as equivalent dose of DSP-0509), blood samples were collected 2 h after injection (n = 3), and plasma cytokines were measured. Data are shown as mean ± SD. Statistical differences were evaluated by the t-test.